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Introduction
The development and advancement of assisted
reproductive technologies (ARTs) has created both
hope and controversy. Infertile couples and individuals
now have many choices when it comes to reproduction.
At the same time these new technologies have created
a huge industry that is in need of regulation. Ethical
and financial issues are at stake. On the one hand,
couples should have autonomy in deciding how to
address fertility issues and start a family. On the
other, it is important to ensure that fertility doctors
and clinics are acting in the best interest of both the
mother and the fetus and are following guidelines to
ensure that procedures are being done in a safe and
ethical manner. The question becomes: what is the best
regulatory model given the ethical and safety issues at
stake?
As with many health care issues, regulation of ART is
driven by various ethical principles. The United States
and Great Britain have approached the regulation of
ART in starkly different ways. While the US has
allowed fertility clinics and doctors to operate largely
unregulated by law, the UK has passed laws to regulate
almost all aspects of reproductive technologies.' These
different policy choices have led to criticism on both
sides and sparked varying opinions on whether the
US should consider a more heavily regulated system.
This paper will focus specifically on the regulation of
fertility doctors, clinics, and research in each country.
The first section addresses the history of regulating
ART in the US and the UK and the current status of
the law. The second section examines some of the
more controversial regulatory issues, the approaches to
regulation taken in each country, and how guidelines
protect the health and safety of patients and fetuses. The
third section addresses whether different regulatory
practices lead to different outcomes in terms of access
and fairness. Lastly, this paper discusses whether
the US would benefit from more federal and state
regulation of ART.

II. Regulation in the United States
A. Federal Law
Regulation of fertility clinics and doctors in the
US comes largely from independent professional
societies, supplemented with some federal and state
law. The Fertility Clinic Success Rate and Certification
Act of 1992 (FCSRCA) requires fertility clinics to
report pregnancy success rates, 2 and also requires
states to develop and administer certification programs
for embryo laboratories. 3 As part of the certification
program the law required, within two years of its
enactment, that the Centers for Disease Control (CDC)
"develop a model program for the certification of
embryo laboratories to be carried out by the States." 4
Embryo laboratories are defined as facilities in
which human oocytes (eggs) or embryos are "subject
to assisted reproductive technology treatment or
procedures based on manipulation."' Essentially,
the laboratories, not the fertility doctors or clinics
themselves, are certified under this program. The law
also specifically states that in developing or adopting
the certification program, neither the Secretary of the
Department of Health and Human Services (HHS) nor
the State could, "establish any regulation, standard,
or requirement which has the effect of exercising
supervision or control over the practice of medicine in
assisted reproductive technologies." 6
The CDC published its final notice of the "Model
Program for the Certification ofEmbryo Laboratories"
in the Federal Register in 1999.7 In deciding on a
model, the CDC consulted with several groups,
including the American Society for Reproductive
Medicine (ASRM), the Society for Assisted
Reproductive Technology (SART), and the College
of American Pathologists (CAP). 8 During the notice
and comment period, there was some concern over
whether to allow unannounced inspections due to
the delicate nature of the work and concerns over
patient confidentiality. 9 The CDC believed that states
adopting the model program should have the option
of unannounced inspections, "so that investigations
of complaints of truly egregious behavior could be
conducted immediately and unannounced."'o There
was also some disagreement over whether there should
be mandatory minimums for training and performance
of certain procedures. Some commentators argued that
the laboratory director should decide "the adequacy of
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each employee's training/experience."" The CDC disagreed, stating that its
minimums were developed to be consistent with ASRM guidelines.12
The Model Certification Program provides requirements for State
administration of the program, including minimum standards for agreements
with laboratories and standards for the laboratories themselves.1 3 These
standards include provisions on personnel qualifications andresponsibilities,
facilities safety, and quality management.14 Although the guidelines do
provide a framework for States, the certification program is voluntary for
both States and the laboratories themselves. The preamble states that, "[w]
hile Congress anticipated that the cost of Federal and State monitoring
and oversight of embryo laboratories would be covered by the fees paid by
participating laboratories, participation ... is voluntary and laboratories not
willing to pay these fees would not be limited in their ability to operate."' 5
According to the Institute on Biotechnology & the Human Future, some
states have based accreditation requirements on the Model Program, but
no state has officially adopted it.16 The result is that there is no federal law
mandating the licensing, accreditation, or inspection of fertility clinics or
embryo laboratories in the US.' 7
B. State Law and Practice Guidelines
States have also attempted to regulate ARTs. Most state laws focus on
insurance coverage of infertility treatment, a topic which will be discussed
in detail in the third section of this paper. Some of these states have chosen
to follow the federal approach of requiring disclosure of success rates.
The focus is on consumer protection and ensuring that clinics are upfront
about the chances that their services will result in a live birth. The main
concern seems to be on cost-effectiveness
for the consumer; i.e., what are the chances
the investment will result in a baby? For
example, in Virginia, physicians are required
to disclose success rates for different age
groups at the particular clinic or hospital
'
'
for the ART procedure being performed.' 8
Laws like these contribute little to the
federal regulations already in place.
Louisiana has some of the strictest and
most comprehensive
laws governing
ART procedures and embryo disposition.
The laws specifically prohibit the sale of any embryo or ovum and the
creation of a fertilized ovum solely for research purposes.' 9 The law
also gives an in vitro fertilized human ovum status as a juridical person
prior to implantation. 20 Patients are given ownership over embryos, but
physicians are responsible for safekeeping. 2 ' The law requires that facilities
meet standards of both the American Fertility Society and the American
College of Obstetricians and Gynecologists, and are directed by a licensed
physician with specialized training in the field. 22 The law also allows for
adoptive implantation when the donor parents renounce parental rights, but
no compensation can be paid or received. 23
Other state laws seem to be reactive rather than proactive, addressing
specific situations as opposed to the broader picture. For example, in
California, lawmakers sprang into action after a scandal at the University of
California, Irvine's Center for Reproductive Health.24 In that case, the clinic
was accused of stealing eggs from nine women who believed they were
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undergoing routine procedures, while instead the clinic was implanting the
eggs in other women. 25 The clinic was also accused of unauthorized use
of an unapproved drug and research misconduct.2 6 After the incident the
California Legislature found that, "[t]he continued risk of these unethical
transfers and implantations without informed consent warrants stronger
legislative protections for California families undergoing in vitro and other
assisted production procedures."27 The resulting law made it unlawful for
providers to "implant sperm, ova, or embryos ... without the signed written
consent of the. . . provider and recipient." 28 The law imposed penalties of
imprisonment for three to five years, a fine of up to $50,000, or both the fine
and imprisonment. 29 Although the California Legislature responded quickly
to the UC-Irvine scandal, the law was narrowly tailored to address consent
issues and did not veer into murkier issues such as embryo disposition or
the implantation of multiple embryos. Moreover, the situation involving the
Irvine clinic was fairly straightforward in terms of illegality. In contrast,
many of the other regulatory issues surrounding ART are not so clear cut.
In the wake of the 'octomom' controversy, in early 2009, both Georgia and
Missouri proposed laws that would limit the number of embryos allowed
to be implanted during a single fertility treatment. 30 As first introduced in
the State Senate, the proposed Georgia bill would have limited the number
of embryos that could be transferred into a woman under forty to two and
to a woman over forty to three. 3 1 That provision did not make it into the
version that eventually passed in the Senate. The bill was not enacted in
the 2009 session and is currently in the House. The version of the bill that
passed the Georgia Senate made it unlawful to create an in vitro embryo
by means other than fertilization or ICSI and prohibited the creation of an
in vitro embryo for any purpose other than
initiating a pregnancy for the treatment of
infertility. 32 In other words, the bill bans
stem cell research. In Missouri, the bill
would have mandated the current ASRM
guidelines limiting embryo transfer be
followed. 33 Both of these bills were opposed
by industry and consumer groups. 34
Other states have taken a more proactive
approach. In New York, for example, the
Task Force on Life and the Law (the Task
Force) released a report entitled "Assisted
Reproductive Technologies: Analysis and
Recommendations for Public Policy" 35 Although the report addressed a
wide variety of issues regarding ART and set forth some guidelines, the Task
Force was reluctant to put the power of law behind its recommendations.
The report found that:
[P]hysicians offering assisted reproduction are under no legal or
ethical obligation to treat every individual or couple who requests
their services . . . physicians are entitled to consider the welfare of
any child who might be born as a result of an assisted reproduction
procedure. Physicians should also develop written policies setting
forth their standards and procedures for the screening of patients and
their partners. Regarding multiple gestations . . . ART practitioners
have a professional obligation to minimize the likelihood of multiple
gestations resulting from the use ofARTs. Specific limits.. . should
36
not be adopted as a matter of state law.

The Task Force essentially relied on professional
societies and individual physicians to set practice
guidelines when it comes to issues like reduction
of multiple gestations and the number of times a
woman can donate eggs. 37. In a few circumstances
the Task Force did recommend state regulation. For
example, the report recommended that the state
enact legislation to establish minimum standards for
obtaining informed consent for ART procedures. 38 The
Taskforce also concluded that, "[t]o provide maximum
oversight of the laboratory procedures involved in
assisted reproduction, New York should participate
in the certification program for embryo laboratories
currently under development by the CDC." 39 The Task
Force noted that, although the program would not be
required under Federal Law, the state should mandate
participation for all of its assisted reproduction
laboratories and that the Department of Health itself
should provide oversight, as opposed to delegating to
private accreditation organizations. 40 As of yet these
recommendations have not been fully adopted.
The Task Force addressed access to ARTs and
discrimination in two distinct ways. In terms of
marital status, the report states that, "[t]he law should
neither prohibit nor require the provision of assisted
reproductive services to unmarried individuals,
including lesbians." 41 When it comes to sexual
orientation, the Task Force leaves access decisions
in the hands of individual providers. In contrast, the
report reinforces that with ART, "[a]s with other
medical treatments, physicians may not refuse . . .
services on the basis on race, color, creed, religion, or
national origin."42 It is troubling that the Task Force
leaves gender and sexual orientation off of this list.
C. Professional Societies
Beyond the limited state and federal laws currently on
the books, the fertility industry in the US is largely selfregulated. Two organizations, the American Society
for Reproductive Medicine (ASRM) and the Society
for Assisted Reproductive Technology (SART), have
taken the lead. The organizations work together to
issue guidelines and best practices. ASRM is a nonprofit organization, "dedicated to the advancement of
the art, science, and practice of reproductive medicine
. .. through the pursuit of excellence in education and
research and through advocacy on behalf of patients,
43
physicians, and affiliated health care providers."
ASRM is a multi-disciplinary organization that.
among other things, issues practice guidelines, works
on legislative issues, and publishes the well-known
journal Fertility and Sterility. 44 SART is a professional
society of member clinics. It represents ninety-five
percent of ART clinics in the US with a mission of

"set[ting] and help[ing] maintain the standards for
ART in an effort to better serve our members and
our patients." 45 SART is involved in data collection,
setting practice guidelines and standards, government
interaction, quality assurance, and ART research.46 In
order to be a SART member, a clinic is required to:
* Have an accredited laboratory. The lab
accreditation program run by ASRM with the
College of American Pathologists (CAP) has
explicit standards on the identification and
documentation of all tissues involved.
* Adhere to all standards and recommendations
of the ASRM Practice Committee.
* Adhere to all standards and recommendations
of the ASRM Ethics Committee. 47
Both ASRM and SART publish a series of practice
guidelines and standards on their websites.
Fertility clinics and doctors are not required to be
members of SART and ASRM, nor is there strict
monitoring as to whether guidelines are actually being
followed. It is estimated that about ten percent of US
clinics are not members, that as many as eighty percent
do not follow guidelines on the number of embryos
that should be implanted during IVF, and that some
clinics violate guidelines by advertising and providing
nonmedical sex selection. 48 Moreover SART can
only punish its member clinics by revoking their
membership status. 49
The American Medical Association (AMA) has also
issued a series of guidelines in order to, "ensure ethical
practices in assisted reproductive technology."50 These
guidelines encourage disclosure of clinic specific
success rates, self-regulation, clinic participation
in credible professional accreditation programs,
reporting unethical practices, full patient consent,
and a payment scheme not based on outcomes.51 The
American Academy of Fertility Care Professionals
(AAFCP) requires its members to pledge adherence to
a code of ethics and report the unethical behavior of
any member.

52

III Regulatio

in Great Britain

In contrast to a largely self-regulatedAmerican industry,
fertility clinics in the UK are heavily regulated by the
government. The Committee of Inquiry into Human
Fertilisation and Embryology was created to address,
among other issues, whether the National Health
Service (NHS) should provide treatment for infertility
and then to address who should be eligible for such
treatment. 53 The committee, established in 1982, was
created in response to the birth of Louise Brown 54 and
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rapid technological developments in the fields ofIVF and embryology.5 5 In
1984 the committee released the "Report of the Committee of Inquiry into
Human Fertilisation and Embryology" (known as the "Warnock Report"). 56
The report lays the groundwork for a robust regulatory framework for ART,
stating that:
We believe that all the techniques require active regulation and
monitoring, even though, as we realize, such restrictions may be
regarded by some as infringing clinical or academic freedom ...
The interests of those directly concerned, as well as those of society
in general, demand that certain legal and ethical safeguards should
be applied. 57
In order to achieve that goal, the report recommended the creation of a, "new
statutory licensing authority to regulate both research and those infertility
services which we have recommended should be subject to control" 58 The
Warnock report envisioned that this new regulatory agency would have
both advisory and executive functions. 59 In its advisory role, the agency
would issue practice guidelines and advise the government on the changing
landscape. 60 The executive role would include granting licenses to doctors
and clinics, both in the public and private sector, and to grant licenses to
researchers in the field. 6 1 The recommendations and framework set forth in
the Warnock report are reflected in the current legislation and regulatory
authority.
Then in 1990, the British government passed the Human Fertilisation and
Embryology Act of 1990 (HFEA). 62 Notably, as recommended by the
Warnock Report, HFEA created the Human Fertilisation and Embryology
Authority (the Authority) to license and monitor fertility doctors and
clinics to ensure compliance with HFEA.63 A glance at the Authority
website practice guidelines compared to those of SART or ASRM reveals
little difference on the surface. Both have sections for patients and donors.
Both will help you find a fertility clinic in your area and report success
rates. Both provide operational and ethical guidance for fertility clinics
and doctors. The difference is clearly in the force behind the guidelines.
Whereas SART and ASRM encourage member clinics to report unethical
practices, the Authority has strict compliance standards and penalties. 64
Failure to comply with HFEA can include both informal warnings and
formal sanctions. 65 For example, the Authority can monitor compliance
with unannounced visits or go so far as to recommend that a practices'
license be revoked or suspended. 66 Formal action is permitted when the
individual responsible for the facility is unable to properly manage 67, when
a clinic has not taken remedial action within a specified timeframe, if there
is a previous history of non-compliance or failure to take remedial actions,
if there is risk to patients, gametes, or embryos, or when there is evidence
of criminal behavior. 68 It is important to note that although there are both
public and private fertility clinics in the UK, the Authority regulates and
inspects all clinics that provide any type of fertility treatments or storage. 69
The Authority has been able to address concerns from critics that regulation
cannot keep pace with technological development. Although the most
sweeping reforms came in 2008, several changes have been made over the
years. Amendments in 1991 and 1996 allowed extended storage periods
for eggs and embryos in certain situations.70 In 2001, the regulations were
amended to allow embryonic stem cell research. 7 ' The 2008 amendments
to HFEA reflect both advances in ART and shifts in societal values. For
example, the amendments extend parental rights to same-sex couples and
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unmarried heterosexual couples. 72 Other highlights include clarifications
on what is allowed in terms of embryo research, specifically in relation
to 'human admixed embryos' 73 and a ban on sex-selection for social
reasons. 74 The Authority is implementing the amendments in three stages.
As of April 9, 2009, the new definitions of parenthood went into effect. 75
Then in October 2009 the amendments to the 1990 legislation took effect. 76
Lastly, as of April 2010, same sex and unmarried couples were able to apply
to be the parents of children born using a surrogate. 77
The 2008 version of HFEA also makes several key changes to the
compliance cycle. The new compliance structure includes a "Risk Tool"
designed to allow facilities to assess their compliance level before being
inspected. 78 The new tool uses generic performance indicators (GPIs) and
a self assessment questionnaire (SAQ). 79 The SAQs are meant to replace
the current pre-inspection questionnaires, a change which the Authority
suggests will allow for more focused inspections. 80
IV Important Regulatory Issues
A. Number of Embryos Implanted During IVF
One of the most controversial regulatory issues is the number of embryos
allowed to be implanted during a procedure. Over forty years after the birth
of Louise Brown, Nadya Suleman, more commonly known as 'octomom',
stirred up the debate when she gave birth to octuplets after a fertility doctor
implanted her with six embryos. 8 1 The case garnered national attention,
but the number of multifetal pregnancies has been on the rise for years. In
fact, between 1980 and 2000, the rate of infants born in triplet or higher
order went from thirty-seven to 181 for every 100,000 births. 82 Although
the entirety of the increase is not attributable to ART, one estimate finds
it responsible for forty percent. 83 Another estimate suggests that ART
accounted for sixteen percent of twin births, forty-five percent of triplet
births and thirty percent of quadruplet births in 2003.84
There are many dangers associated with high order pregnancies. Generally
speaking, the more fetuses carried to term, the greater likelihood of
premature births and the lower the birth weight of each fetus. 85 Multiples
are also more likely to suffer from a variety of complications, congenital
malformations, and long-term handicaps. 86 Even twins have a sixty percent
greater chance of being born prematurely. 87 In addition to the danger to
the fetuses and infants, there are also more instances of maternal health
problems in women carrying multiples. 88 Despite the dangers associated
with multiple gestation, "there is an attitude among infertility physicians
that the wishes of the infertile couple must be respected. This reflects a
certain prioritization of values, according to which the desire of the couple
to have a baby is more important than avoiding risks to the offspring." 89 The
focus is on patient autonomy rather than best practices.
Another motivation to implant more embryos is linked to doctor success
rate. In the 'octomom' case, the octuplets were not Nadya's first foray into
IVE In fact, between 2000 and 2006, Nadya gave birth to six children,
including a set of twins, as a result of fertility treatments. 90 Those five live
births represented just over twenty percent of the total live births to women
under thirty-five at the clinic in question during the six-year span. 9 ' This
led many to believe that Nadya's doctor was using her to, "boost his stats
and improve his standing in the highly competitive and lucrative fertility
field." 92 More disturbing is the revelation that Nadya was implanted with

six embryos for each of the pregnancies. 93 The implantations were a clear
violation of professional guidelines that state patients under the age of
thirty-five should consider implantation of only one embryo, and should
not be implanted with more than two embryos. 94 Under no circumstances
do the guidelines recommend implanting more than five embryos at any
stage. 95
Even though Nadya's doctor violated the guidelines he received no
penalization other than the media and professional backlash. Although
Nadya's doctor was expelled from membership in ASRM and SART,
there is nothing stopping him from continuing to practice. 96 The high
danger to both Nadya and her unborn children was at odds with the low
repercussions for Nadya's doctor. That tension is present in the guidelines
themselves, which state first that, "[h]igh-order multiple pregnancy (three
or more implanted embryos) is an undesirable consequence (outcome) of
assisted reproductive technologies (ART). Multiple gestations lead to an
increased risk of complications in both the fetuses and the mothers." 97 Only
two paragraphs later the guidelines state that, "[s]trict limitations on the
number of embryos transferred, as required by law in some countries, do
not allow treatment plans to be individualized after careful consideration
of each patient's own unique circumstances." 98 Cleary ASRM and SART
have traditionally supported a deregulated industry that allows the greatest
flexibility for doctors, clinics, and patients. Yet at the same time these
professional societies encourage safe and ethical practices. Cases like
Nadya's, where a doctor manipulates the process in order to report greater
success rates, demonstrate the need for a more consistent and compliance
oriented regulatory environment in which there are true penalties for
dangerous procedures.
In the UK, the Authority has similar guidelines for fertility clinics in terms
of actual numbers. The law mandates that in a single cycle no more than two
embryos can be implanted for women under forty, and no more than three
for women over forty.99 Also, at a minimum, clinics must keep individual
records explaining the reasons for implanting three embryos and have a
"multiple births minimisation strategy."' 00 In cases where multiple embryos
are implanted into a woman who meets the criteria for single embryo
transfer, the clinic must also include an explanation for the action and a
note "confirming that the risks associated with multiple pregnancy have
been fully discussed with the patient."' 0 ' Failure to comply can result in
any of the informal and formal penalties discussed in the previous section.
B. Sex-Selection & Preimplantation Genetic Diagnosis
Another controversial issue is sex-selection and preimplantation genetic
diagnosis (PGD). PGD is defined as the process of testing to see whether
a specific mutation from one or both parents has been transmitted to an
embryo.' 02 First, it is important to distinguish between sex-selection for
medical reasons and sex-selection for non-medical reasons. Sex-selection
for medical purposes allows parents to prevent the transmission of sexlinked genetic diseaseS.' 03 ASRM explicitly approves of preimplantation
sex-selection when used for medical reasons because of its ability to limit
disease and suffering and the inherent lack of gender bias. 1 04
In the UK, HFEA not only specifically bans sex-selection for non-medical
reasons, but it also states that an embryo may only be tested to determine
if the embryo has a "gene, chromosome, or mitochondrial abnormality"
that would impact whether it would result in a live birth or when there is

a particular risk of the embryos having such an abnormality.' 0 PGD can
only be carried out in two specific instances. The first is when there is a
"particular risk" that the embryo will have a "genetic, mitochondrial or
chromosomal abnormality" that will result in a "serious disability, illness or
medical condition."106 In that situation PGD is used to determine whether
the embryo has the specific genetic abnormality. The second situation in
which PGD is allowed in the UK is for medical sex-selection. In that case
PGD is allowed "where there is a particular risk that any resulting child
will have or develop a gender related serious disability, illness or medical
condition."107 In that situation the Authority must first determine that the
condition in question affects only one sex or disproportionately affects
one sex more than the other.108 These are mandatory requirements that all
fertility clinics in the UK are required to follow.
The arguments in favor of sex-selection for non-medical reasons center on
reproductive choice. The logic is that individuals should be allowed to make
their own choices when it comes to bearing children and that choosing the
sex of a child is a natural extension of that right.109 Other arguments in
favor of sex-selection include, "social goods such as gender balance or
distribution in a family with more than one child, parental companionship
with a child of one's own gender, and a preferred gender order among one's
children.""l0 In a 2001 report published in Fertility and Sterility, ASRM
concluded that preconception, "sex selection aimed at increasing gender
variety in families may not so greatly increase the risk of harm to children,
women, or society that its use should be prohibited or condemned as
unethical in all cases."" Preconception sex-selection is distinct from PGD
because it takes place before the egg is fertilized, often in the form of sperm
separation.
There are several arguments against engaging in sex-selection for nonmedical reasons. One concern is that there is a 'slippery slope' once parents
are given control over "nonessential characteristics of children."ll 2 if
parents can decide the gender of their child, why not eye or hair color?
Another argument is that engaging in sex-selection encourages gender
discrimination and could in fact lead to sex ratio imbalances. In terms of
sex-selection for "social reasons" HFEA specifically bans all "practices
designed to ensure that a resulting child will be of a particular sex."11 3 This
includes both PGD and preconception sex-selection.
ASRM's guidelines regarding sex-selection have not stopped fertility
clinics and doctors in the US from exploring the notion of using PGD
to select the gender and even other physical traits of a child. In fact, the
Fertility Institutes clinic in Los Angeles advertises that it can guarantee
the gender of a child, stating that, "If you want to be certain your next
child will be the gender you're hoping for, be aware that no other method
comes close to the reliability of PGD. While traditional sperm-screening
techniques have a success rates of 60-70% , only PGD offers virtually 1000%
accuracy."ll4 Sex-selection, which is offered for both fertile and infertile
couples, is quoted as costing $18,490."s
Although there is not yet any mention of it on the website, the Fertility
Institutes also recently said that it would begin offering services to help
6
couples select other physical traits in their unborn children.11 The clinic
claims that the service has been requested by several couples.11 7 A survey
conducted by the New York University School of Medicine revealed that
of 999 people seeking genetic counseling most supported PGD to screen
for certain genetic diseases.118 This reflects the stance taken by ASRM and
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other professional organizations. Notably, however,
ten percent of patients surveyed said they would use
genetic testing to determine athletic ability and another
thirteen percent supported genetic testing to ensure
superior intelligence.119 The director of the Fertility
Institutes is quoted as saying that "[t]his is cosmetic
medicine. Others are frightened by the criticism, but
we have no problems with it."120
C. Controversial Techniques and Research
Another interesting issue that arises with regulation is
the use of experimental or investigational techniques.
In the UK, the Authority works with professional and
scientific organizations to develop policy regarding
fertility treatment and human embryo research.121
HFEA and the Authority specifically regulate what
is allowed in terms of research techniques. Currently
much of the new research revolves around preventing
the transmission of genetic defects and diseases.1 22
In the US, the use of experimental ART techniques
is not regulated. Instead professional societies offer
guidance. ASRM defines experimental procedures
as such until there is sufficient published medical
evidence as to their, "risks, benefits, and overall safety
and efficacy."' 23 ASRM warns that experimental or
investigational procedures should not be marketed as
established or routine. 124
Despite guidelines, doctors in the U.S. do turn to
experimental procedures in extreme cases. In 1993,
Susan and Bill McNamara began to see a fertility
specialist after they were unable to conceive on their
own. 125 They faced a myriad of fertility issues. Bill's
sperm count was extremely low, Susan had a misshapen
uterus that would require major surgery to hold a fetus,
and Susan was literally allergic to Bill's sperm.126 The
McNamaras turned to a technique known as co-culture,
when human embryos are grown in the uteruses
of other species or on fallopian tube cells.127 The
practice began in the late 1980s, but went unnoticed
by the Parental Drug Association (PDA) until 2002
when it began sending letters telling clinics to stop the
unapproved use of co-culture.' 28 Even co-culture using
human cells poses the risk of transmission of infectious
disease from the cell line to the embryo.' 29 Despite
the risks of disease transfer from animal to human,
the PDA did not ban co-culture, but instead requires
clinics to fill out an Investigational New Drug (IND)
application.' 30 The PDA also recommended life-long
monitoring, including reporting unusual symptoms
and abstaining from blood and tissue donation, for coculture children and families.' 3 ' On the upside, Susan
and Bill were able to have three children as a result
of co-culture. On the other hand, at least one of their
children has a birth defect that may have been caused
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by the use of ART to conceive. 132 In contrast to the
more permissive stance taken by the PDA, in 1990 the
HFEA specifically banned placing an embryo in any
animal. 133
Another procedure that has raised concern is
intracytoplamic sperm injection (ICSI). ICSI involves
injecting a single sperm directly into a human egg.134 In
contrast, typical IVF involves placing an egg in a petridish with thousands of sperm and letting fertilization
occur on its own. 135 ICSI is generally used to help
couples with male fertility issues, such as low numbers
of or poor quality sperm.136 One risk of ICSI is that
the egg will be irreparably damaged by the needle.1 37
Additionally some doctors believe that ICSI children
have slightly higher chances of having sex chromosome
abnormalities passed on through defective sperm.138 n
contrast to co-culture, ICSI is a widely used procedure
that is no longer considered an experimental procedure
by ASRM.139 In the UK, HFEA requires that clinics
provide couples using ICSI with information regarding
the risks, including, "a reduced number of eggs being
available for treatment (compared to IVF), due to eggs
being immature or damaged by the process of ICSI" 40
and that, "children conceived [will have] . . . inherited

genetic, epigenetic or chromosomal abnormalities
(including cystic fibrosis gene mutations, imprinting
disorders, sex chromosome defects and heritable subfertility)."'41 ASRM recommends that couples dealing
with male infertility be counseled before using the
ICSI technique to conceive. 142
Despite the risks of experimental procedures like coculture, and less experimental procedures like ICSI,
proponents of a de-regulated infertility industry
argue that each individual patient has different needs
and responds differently to treatment. The question
becomes whether it is fair to outlaw or regulate
certain practices that might allow a couple to have a
baby when they otherwise could not. In September
2009, ASRM published a report addressing the issue
of fertility treatment for couples with little or no
chance of success. 143 The article recognized that,
"[m]isunderstandings may arise when couples and!
or individuals seek to initiate or continue treatment
regarded by practitioners as having either a very low or
virtually nonexistent chance of success."1 44 Although
ASRM concluded that in cases of futility, it is unethical
to continue treatment, it stressed that clinics should
remain flexible based on the individual patient and
14
potential differences of opinion among doctors. 5
D. Embryo Mix-ups
Recently several cases of embryos being accidently
implanted into the wrong woman have raised concerns

over laboratory policies in both the US and the UK.
In the US, the most recent incident involved an Ohio
woman who received the embryo of another couple.146
The Ohio couple hoped to use their remaining frozen
embryos to have a fourth child, but was informed early
in the pregnancy that there had been a mix-up.147 The
American Fertility Association (AFA), a non-profit
professional organization, issued several statements in
response to the incident. In their legal statement, the
AFA addressed only the custody issues at stake and
did not discuss possible repercussions for the clinic.148
It is unclear exactly what those repercussions, if any,
would be.
Another case involved a New Orleans hospital where
it was discovered that as many as 100 couples were
affected by a labeling error.149 Although a spokesperson
said there was no reason to believe that any embryo was
actually implanted in the wrong woman, the program
described the problem as a "significant labeling
issue." 150 In addition to the possibility that embryos
were wrongly implanted, several frozen embryos were
lost or accidently destroyed.' 5 '. At least two couples
whose embryos were lost have since filed suit. One of
the couples was told that even if their embryos were
found, it was determined that required screenings for
sexually transmitted diseases had not been done prior
to freezing.152 In a San Francisco case, all of a couple's
embryos were destroyed without their consent when
it was discovered that the embryos were implanted
with the wrong sperm.153 A lawyer for the couple said
that, "There is no regulation of these fertility clinic
laboratories where the particular jobs like fertilizing
eggs or preparing embryos for transfer are done. If
there was better regulation, I think we would not have
these kinds of problems."' 54
These problems are not unique to the US. From
2007 to 2008, the Authority reports that two embryo
or gamete mix-ups occurred.' 5 5 In 2004, a clinical
embryologist in London became concerned when she
discovered errors in patient notes, including missing
56
She was ignored
signatures and security checkS.'
by her superiors and eventually contacted the HFEA,
which determined that although she had breached
patient confidentiality by bringing the evidence to
light, she nevertheless acted in the best interests of
her patients.' 57 The hospitals in question responded
by introducing new procedures to ensure proper
labeling.' 58
Current HFEA guidelines classify an embryo
misidentification or mix-up as a "serious adverse
event" for which responsible parties must provide the
Authority with a report analyzing the cause and effects
of the event. 159 The Authority can then take corrective

measures. Recently, the Authority has begun to publish
incident reports on its website.160 Previously, the
Authority made the determination not to publish these
reports because, "[w]e wanted to build trust, to assure
centres that our aim was to learn and promote higher
standards, not to punish human error."161 In these
reports, embryo mix-up ups are classified as grade
"A" incidents, which are the most serious offenses.
Despite new reporting guidelines, the issue of embryo
mix-ups in the UK has created tension between
affected couples and the Authority, which is hesitant
that stricter guidelines "will drive our patients abroad
for treatment because our clinics are more severe." 162
Despite such tension, the fact that there is a central
body to investigate and report these incidents provides
better consumer information and gives clinics added
incentive to follow regulations.
V Access/Fairness

An additional issue that comes up in the regulation
debate is deciding who should have access to ART.
When Nadya Suleman gave birth to octuplets, much
of the uproar surrounded the fact that she was an
unemployed single mother on disability assistance with
six children in addition to the eight infants.163 Beyond
the medical issues discussed in the previous section,
Suleman's case upset people in terms of her ability
to mother and provide for all fourteen children.1 64
The public sentiment was that Suleman never should
have been allowed to conceive using ART procedures.
These issues go to the heart of the access dilemma.
Should there be limitations on who has access to ART?
If so, who should decide?
There are definite access issues on both sides of the
regulatory model. In the US, access to IVF depends
on whether an individual or couple can either
afford the procedures on their own or whether their
private insurance plan happens to cover certain ART
procedures, most commonly IVE1 65 A few states
have passed laws regarding insurance coverage for
certain ART procedures. For example, in Arkansas, all
insurers that cover maternity benefits are also required
to cover IVE166 The law exempts HMOs and also
has strict eligibility requirements. 67 Arkansas also
requires that the patient's eggs be fertilized with her
spouse's sperm.' 68 Clearly, this eligibility requirement
makes it considerably more difficult for same-sex
couples to access IVF and other ART procedures.
It also discriminates against single women seeking
to have children. On a more positive note, the law
promotes safety and best practices by requiring that
the IVF procedure be performed in facilities certified
by the Arkansas Department of Health.' 69
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In Illinois, insurance policies that provide coverage to more than twentyfive individuals and that already provide pregnancy benefits are required
to cover the diagnosis and treatment of infertility.170 The coverage includes
a wide variety of ART, including IVF, artificial insemination, and gamete
intrafallopian transfer. The Illinois law also requires that facilities meet
the standards set forth by either ASRM or the American College of
Obstetricians and Gynecologists.17' Although the law does not require that
patients be married, it does require that patients have "used all reasonable,
less expensive and medically appropriate treatments and [are] still unable
to get pregnant or carry a pregnancy."' 72 The implication is that a samesex couple seeking fertility treatments will not receive coverage unless
infertility is medically established. Both New York and California require
some insurers to cover treatment for infertility, but specifically exclude IVF
from the mandate.1 73
The wide variety of state laws makes ART procedures more accessible in
some states than others. It also means that, in some states, fertility clinics
are required to follow best practice guidelines in order to accept payment
from insurance companies, but there is no consistent mandate. The concern
over mandating insurance coverage for ART procedures goes beyond cost
concerns. In fact, one estimate suggests that even if usage of IVF rose 300
times when added to an employer health plan, the average premium would
only increase by nine dollars a year.174 The thought is that despite the high
costs of IVF, the fraction of the population that needs the treatment is still
relatively low.175
The debate about covering IVF also focuses on cost effectiveness. Despite
the popularity of the procedure, success rates are still relatively low and
vary greatly across clinics. A 2007 survey of all SART member clinics
revealed that for women under thirty-five, about forty percent of cycles
using fresh embryos from non-donor oocytes resulted in live births. Thirtyfour percent of cycles using thawed embryos resulted in live births for the
same population.176 The numbers are significantly lower for women over
thirty-five, with a live birth percentage rate of just over thirty percent for
both fresh and thawed embryos.1 77 Given these success rates, the question
becomes whether it is cost effective for insurance companies to cover IVE
Moreover, should companies be allowed to limit access for older women
who are less likely to get pregnant? Some state insurance mandates do
address the age issue. For example, Connecticut law requires that the
covered individual be under the age of forty.178 In New York, patients have
79
to be between the ages of twenty-one and forty-four.1
Without help from insurance, IVF can cost between $10,000 and $15,000
per cycle.' 80 For women under thirty-five, this means that the average cost
to get pregnant is more like $34,000 because it generally takes more than
one cycle. For women over forty, that price tag can exceed $100,000. The
high prohibitive cost of fertility treatments in the US means, in most cases,
that only the wealthy have access. In her article discussing access and
regulation, June Carbone argues that access to fertility treatments allows
wealthier women to wait longer to have children and accumulate greater
wealth and education.' 8' In contrast, "[f]or the poor, and particularly poor
African Americans, waiting may instead mean permanent childlessness .. .
The cost of the new reproductive technologies places them out of the reach
1 82
of poorer women."
In the UK, the NHS will cover ART procedures, but has strict regulations
as to who is eligible and how many times a person can receive treatment. 183
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The NHS website explains that, "[f]ertility treatment, funded by the NHS,
currently varies across the UK. In some areas, waiting lists for treatment
can be long. The criteria you must meet in order to receive treatment can
also vary."' 84 These variations are regional, based on what is known as
the 'postcode lottery'. The term 'postcode lottery' describes "seemingly
random countrywide variations in the provision and quality of public
services."1 85 Despite the existence of the NHS, there is not a standard of
care and instead access to infertility services depends on where you live.
The website includes a section on seeking out private treatment, which
for a cycle of IVF is estimated to cost between E4000 and E8000.186 The
NHS will typically cover one IVF cycle per eligible couple.187 Although
eligibility determinations are made locally by primary care trusts (PCTs)188,
the basic eligibility criteria is that the women is between the ages of twentythree and thirty-nine and that either the reasons for infertility have been
identified or the couple has been experiencing fertility problems for at least
three years.189 The guidelines also note that priority is typically given to
couples without other children.190 Despite the fact that the NHS covers
fertility treatments, many couples in the UK end up using private services
and are left in a similar position to their American counterparts.191 That is,
access to fertility treatments often times ends up relying on wealth despite
the existence of nationalized health care.
One problem is the lack of standards across PCTs. PCTs have the freedom to
set their own eligibility requirements. Different PCTs have different criteria
for eligibility. For most, the maximum age of eligibility is thirty-nine, but
some PCTs have a maximum age of thirty-seven.192 Another variation in
criteria is the minimum length of relationship or period of infertility. The
minimum ranges from one to three years, while some simply require that
the relationship be "stable."' 93 At least forty-six PCTs require infertile
women to give up smoking in order to be eligible for treatment. 194 Some
even require that the woman's partner also be a non-smoker. More troubling
are some of the other "social criteria" that PCTs set to exclude certain
women, including weight, sexual preference, and whether the individual
or their partner have other children.195 According to one report, fifty-four
percent of PCTs bar access to IVF for couples that have other children,
including when the partner not seeking to get pregnant has children from a
previous relationship.196 In one case, a woman trying to conceive was told
that if she found a partner other than her husband of three years, who had
children from a previous relationship, she would be immediately eligible
for NHS funded IVE1 97 At least six PCTs explicitly deny IVF access to
same-sex couples, while most others have an unspecified policy.198
In 2004, The National Institute for Health and Clinical Excellence
(NICE) recommended that infertile women be given three free cycles of
IVE199 According to a 2008 article, only nine of 151 PCTs followed that
recommendation. Four were not offering IVF at all (that number is now
down to one).200 According to the article, "[e]ven where IVF treatment
is funded, there is wide variation in the eligibility criteria set by different
PCTs . .. across the whole of South Central ... only women aged between
36 and 39 are eligible and only if neither partner has any children from a
previous relationship. .. In many areas women under the age of 25 cannot
have free IVF, while [some] women will not be treated until they reach
the age of 35."201 As discussed, success rates are significantly lower for
women over the age of thirty-five. In one case, a couple was denied access
to IVF because the woman was only twenty-six years old and the eligibility

requirements stated that the woman had to be between thirty-five and thirtyeight years old. 202 In that case the couple had been trying for six years
and was told that IVF was their only possibility for conception. 203 If that
particular couple lived in a different part of the country, they would have
had no problem getting approved for treatment.
One concern is that the failure to fund the recommended treatments will
increase instances of multiple births because of the pressure to succeed in
the first cycle. 204 The lack of funding for multiple cycles of IVF frustrates
the Authority's goal of minimizing multiple births. While clinics are
required to have minimization strategies, PCTs that refuse to fund the
recommended cycles are de-incentivizing the policy choice. This will
either result in clinics ignoring guidelines on the number of embryos they
implant or in much lower success rates for patients trying to get pregnant.
According to the National Infertility Awareness Campaign, "'with the
move to single embryo transfer, it is even more important to end this totally
unacceptable and allow patients access to the treatment promised to them
205
by the government."'
There is also controversy in the UK surrounding the use of surrogates. Not
all PCTs will fund IVF for women using a surrogate. 206 The regulations
are unclear. For example, "guidance from the National Institute for Health
and Clinical Excellence states that where reason for the infertility is known
patients should be fast-tracked for NHS funded treatment but it goes on
to say surrogacy lies outside the remit of guidance." 207 The most recent
version of HFEA only addresses the illegality of commercial surrogacy
arrangements. 208 In the UK, commercial facilitation of surrogacy is a crime
and persons seeking a surrogate either has to seek out a friend or relative or
209
turn to one of a few non-profits that help match parents with surrogates.
The US has taken a similarly confusing approach to surrogacy. The
laws differ greatly state to state. For example, of the six states that allow
surrogacy contracts, three only allow gestational surrogacy 210 and three only
allow for uncompensated surrogacy agreements. 211 In eleven states and the
District of Columbia surrogacy is illegal in some or all circumstances. 212 In
cases where a surrogate is necessary, access in both countries, once again,
depends on where you live.
VL Should the US Regulate ART?

comes to setting ART policies.216 Without federal regulation there is more
room for divergent ethical and political viewpoints. 217 Moreover, "[r]ules
imposed in the US by an HFEA-type regulatory body appointed by an
executive elected by a bare majority of the population would face fierce
court challenges and political opposition." 218 It would be difficult to have
a consistent policy with power shifts from one party to another. The US
experience with stem cell research is demonstrative; with policy shifting
from funding the creation of stem cells for research during the Clinton
Administration to a much more limited policy under Bush. 219 Now, under
the Obama Administration, the pendulum is swinging back towards full
support for federal funding of stem cell research.
In the US there is a heavy focus on choice and autonomy when it comes
to making health care decisions. 220 There is also general suspicion of
government regulation. 22 1As was evident in the current debate over health
care reform, many Americans feel that the government should stay out of
personal health care decisions. The US has avoided federal regulation of
ART over and over again. In the early 1990s IVF was one of only a few
medical procedures to be "explicitly excluded from the standard health
benefit package in the Clinton administration's Health Security Act." 222
Also telling is the fact that the one federal law currently in place, by
requiring doctors to disclose success rates, has actually ended up putting
pressure on doctors to ignore guidelines limiting the number of embryos
implanted in order to maximize success at a minimal cost. 223
The argument against centralized regulation of ARTs focuses on the
autonomy of the individual to make his or her own reproductive choices.
The bioethicist John Robertson has been instrumental in leading this side
of the debate. He believes in "procreative liberty" or what he describes
as protecting, "the freedom to contract for the provision, receipt, transfer,
and storage of embryos and gametes, when necessary to achieve protected
reproductive goals." 224 For him these rights come from the Constitution
and are fundamental. 225 As fundamental rights, Robertson believes they
should be free from governmental constraint.226 Most recently Robertson
has been involved in the argument over reprogenetics, or the use of assisted
reproduction and genetics to engineer embryos. 227 He argues against a
centralized regulatory scheme, claiming that to date the system of "muddling
228
through" has worked for other applications of assisted reproduction.

Currently policies and regulation of ART in the US are comprised of a
combination of minimal federal law, varied state laws, and guidance
from professional societies. There are pros and cons to adopting a federal
regulatory scheme for ARTs in the US. One of the pros of the UK model is
that there is better protection against, "unscrupulous practices of unethical
providers who have made headlines and eroded confidence in the US
system." 213 There is also, "access to better information about individual
clinics and providers." 214 The regulatory model in the UK has led to better
consumer protection, which coincidently was one of the goals that drove the
US to enact the FCSRCA. The stated purpose of the bill was to, "provide
the public with comparable information concerning the effectiveness of
infertility services and to assure the quality of such services by providing
for the certification of embryo laboratories." 21 5 A more comprehensive
regulatory system in the US would likely provide better protection for
consumers.

At the same time, without regulation of fertility clinics, doctors are able
to ignore or pick and choose which guidelines to follow when it comes to
ART procedures. The existence of a Constitutional right does not mean
that regulation is impossible or unnecessary. Without a national regulatory
agency akin to the Authority in the UK, there is no way to ensure that clinics
are following guidelines when it comes to health and safety. Professional
societies in the US argue that regulation would limit the type of treatments
available to women desperately seeking fertility treatments. 229 They make
a personalized medicine argument against strict regulations. 230 They also
23
argue that there is no way for the law to keep pace with technology. ' At
the same time, a closer look at regulation in the UK demonstrates that the
HFEA does allow treatment options to vary depending on the patient, while
232
Moreover the most
requiring documentation and informed consent.
recent amendments to HFEA have been able to keep up with technological
and social advances. 233

One theory as to why a federal regulatory scheme would be difficult in the
US is the idea that there is a "lack of national moral consensus," when it

When it comes to mandating guidelines and licensing for clinics and
doctors, the US has much to learn from the UK's centralized regulatory
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scheme. But, that does not mean that a completely centralized regulatory
body is the only option. States, as opposed to the federal government,
typically regulate medical practice.234 Given the recent debates over
federal government intervention into health care, one option in the US
is to mandate laws like the recommendations set forth by the CDC. That
is, create minimum requirements for the regulation of ART that states
can use to create their own laws, so long as those laws do not violate the
constitution. A recent study of the Constitutional implications of regulating
ART concluded that pursuant to their police powers, States can regulate
ART "in order to protect the health, safety, and welfare of their citizens"
but that any regulation distinguishing "socially disfavored groups" will be
strictly scrutinized.235 The author makes a compelling argument that states,
"are the most natural regulators of procreation," because with their policing
powers states hold, "the kinds of governmental interests that the Supreme
Court has held may justify interfering with individual's reproductive liberty
- public welfare, health, and safety."236
Another option is to integrate the current self-regulating scheme with
federal enforcement. In the US, critics of regulation ask whether a federally
regulated regime would be effective without a national health care system
akin to that in the UK. The reality is that the Authority in the UK is able
to regulate both public and private facilities. Although there are lingering
access issues as a result of the NHS, these are not a direct result of the
guidelines that regulate safety and best practices. Just as other agencies
within the Department of Health and Human Services regulate private
industry; it would be possible to create a new agency to regulate the
fertility industry. Considering the current role that professional societies
play in regulating ART in the US, it makes sense to allow them to continue
setting practice guidelines and leading the industry forward. The US
should consider creating a regulatory enforcement agency that creates real
consequences for clinics and physicians that violate these professional
guidelines.
No matter what type of regulatory scheme emerges, the tide in the
professional community does seem to be shifting towards support for
greater regulation. The controversy over octomom re-ignited the regulation
debate in the US. In the wake of the media storm, ASRM issued a press
release stating that, "[t]he time has come for policymakers to sit down with
the leading experts in the field to explore ways we can codify our standards
to give them additional regulatory teeth."237 ASRM also revoked the
membership of Nadya's doctor.238 The statement prompted responses on
both sides of the issue. On the one hand, some providers were outraged. The
former president of ASRM was quoted as calling the willingness to regulate
"ridiculous," stating that "[e]veryone has the goal of not having multiples,
but the more you have a regulatory agency interfere with your ability to
239
practice medicine, the more unintended consequences will occur."
Another doctor expressed that the "invitation" to regulate would have
serious consequences for the doctor-patient relationship: "[c]odification
of these standards would be a tragic error that would severely restrict the
ability of physicians to provide appropriate, individualized medical care to
their patients." 240 On the other hand, proponents of regulation praised the
statement as long overdue. A representative of the Center for Genetics and
Society, a group that advocates for regulation, blamed the problem partly
on competition between fertility clinics, and stated that, "[t]here are a lot of
fertility doctors who have lots of integrity and are completely responsible,
but it's a situation where, because of the lack of public policy, it creates -
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and encourages - bad apples." 241 Despite some opposition, the fact that
SART and ASRM are moving in a direction that supports greater regulation
is a promising step towards addressing the current patchwork of regulations
and guidelines in the US. If the federal government does decide to regulate
ART, either through a centralized agency like the Authority in the UK or
by requiring that States create their own guidelines, it will be important to
have the support of these professional organizations that have traditionally
set forth practice guidelines.
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